- Home
- DXYZ vs ORIC Comparison
DXYZ vs ORIC Comparison
Compare DXYZ & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXYZ | ORIC |
|---|---|---|
| Founded | N/A | 2014 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.5M | 837.3M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DXYZ | ORIC |
|---|---|---|
| Price | $27.07 | $8.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 2.1M | ★ 2.3M |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.71 | $3.90 |
| 52 Week High | $50.50 | $14.93 |
Technical Indicators
Market Signals| Indicator | DXYZ | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 37.51 |
| Support Level | $25.10 | N/A |
| Resistance Level | $29.14 | $13.46 |
| Average True Range (ATR) | 2.13 | 1.05 |
| MACD | 0.21 | -0.38 |
| Stochastic Oscillator | 30.42 | 27.88 |
Price Performance
Historical ComparisonAbout DXYZ Destiny Tech100 Inc.
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It is designed to be an investment portfolio of the Top 100 High-Growth Tech Companies.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.